Joe Turner, former Chief Financial Officer at Myogen (now Gilead (NASDAQ: GILD)), has joined the privately held Los Angeles-based Kythera Biopharmaceuticals Board of Directors. Not only is Joe an incredibly talented executive and individual but most selfishly he too has had a profound impact upon my personal life and professional development, and for that I [...]

• 325http://clsdf.com/2008/02/kythera-lands-joe-turner-on-board/Kythera+Lands+Joe+Turner+on+Board2008-02-22+14%3A57%3A00admin

QUESTION: What do ZostaVax®, Kineret® and Macugen® have in common… ANSWER: They are all FDA approved first-in-class commercialized products originating from University of Colorado intellectual property. Want to learn more about these products and the rich product pipeline portfolio at the University of Colorado? Then take a listen to this podcast featuring David Allen, Ph.D., [...]

• 213http://clsdf.com/2007/09/3-commercialized-products-counting/3+Commercialized+Products+%26amp%3B+Counting%212007-09-08+23%3A04%3A00admin

You may have seen the news yesterday on the Archemix and Merck KGaA deal for the use of the SELEX® technology in the oncology field. Well Cambridge and Germany are a long way from Colorado, or are they… The origins of the Archemix/Merck deal may be traced back to the first floor of Porter Bioscience, [...]

• 182http://clsdf.com/2007/06/selecting-a-selex%c2%ae-pathway/Selecting+a+SELEX%C2%AE+Pathway2007-06-12+15%3A41%3A00admin

And the Colorado M&A hits keep on coming…Merck & CO. (NYSE: MRK) announced the $1.1 billon acquisition of San Francisco headquartered Sirna Therapeutics, Inc. (NASDQ: RNAI). Why does an acquisition story about an acquirer from New Jersey and an acquiree from San Francisco make it onto the virtual pages of Colorado Life Science Deal Flow [...]

• 130http://clsdf.com/2006/10/when-it-rains-it-pours/When+It+Rains+It+Pours...2006-10-31+01%3A16%3A00admin